Human papillomavirus type 16 E2- and L1-specific serological and T-cell responses in women with vulval intraepithelial neoplasia

Journal of General Virology

Volumn 84, Issue 8, 2003, Pages 2089-2097

  Davidson, Emma J ^a,b   Sehr, Peter ^c   Faulkner, Rebecca L ^a,b   Parish, Joanna L ^d   Gaston, Kevin ^d   Moore, Richard A ^e   Pawlita, Michael ^c   Kitchener, Henry C ^b   Stern, Peter L ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; ONCOPROTEIN; VIRUS PROTEIN; VIRUS VACCINE;

CARBOXY TERMINAL SEQUENCE; CARCINOMA IN SITU; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEROLOGY; SEROTYPE; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION; VIRUS PARTICLE; VOLUNTEER; VULVA CANCER; WART VIRUS;

ADULT; ANTIBODIES, VIRAL; CAPSID PROTEINS; CARCINOMA IN SITU; DNA-BINDING PROTEINS; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; T-LYMPHOCYTES; TUMOR VIRUS INFECTIONS; VULVAR NEOPLASMS;

ANIMALIA; DNA VIRUSES; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS; PAPOVAVIRIDAE;

EID: 0042668502     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.19095-0     Document Type: Review

References (45)

1. Bauer, H. M., Greer, C. E. & Manos, M. M. (1992). Determination of genital human papillomavirus infection by consensus PCR amplification. In Diagnostic Molecular Pathology: a Practical Approach, vol. II, pp. 131-152. Edited by C. S. Herrington & J. O. D. McGee. Oxford: Oxford University Press.
2. Bontkes, H. J., de Gruijl, T. D., Bijl, A. & 7 other authors (1999). Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia. J Gen Virol 80, 2453-2459.
3. Borysiewicz, L. K., Fiander, A., Nimako, M. & 10 other authors (1996). A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347, 1523-1527.
4. Carter, J. J., Koutsky, L. A., Wipf, G. C., Christensen, N. D., Lee, S. K., Kuypers, J., Kiviat, N. & Galloway, D. A. (1996). The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174, 927-936.
5. Davidson, E. J., Brown, M. D., Burt, D. J., Parish, J. L., Gaston, K., Kitchener, H. C., Stacey, S. N. & Stern, P. L. (2001). Human T cell responses to HPV-16 E2 generated with monocyte-derived dendritic cells. Int J Cancer 94, 807-812.
6. de Jong, A., van der Burg, S. H., Kwappenberg, K. M. & 9 other authors (2002). Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 62, 472-479.
7. De Roda Husman, A. M., Walboomers, J. M. M., van den Brule, A. J. C., Meijer, C. J. L. M. & Snijders, P. J. F. (1995). The use of general primers Gp5 and Gp6 elongated at their 3′ ends with adjacent highly conserved sequences improves papillomavirus detection by PCR. J Gen Virol 76, 1057-1062.
8. Dillner, J., Lenner, P., Lehtinen, M., Eklund, C., Heino, P., Wiklund, F., Hallmans, G. & Stendahl, U. (1994). A population-based seroepidemiological study of cervical cancer. Cancer Res 54, 134-141.
9. Graham, D. A. & Herrington, C. S. (2000). HPV-16 E2 gene disruption and sequence variation in CIN 3 lesions and invasive squamous cell carcinomas of the cervix: relation to numerical chromosome abnormalities. Mol Pathol 53, 201-206.
10. Hamsikova, E., Novak, J., Hofmannova, V., Munoz, N., Bosch, F. X., de Sanjose, S., Shah, K., Roth, Z. & Vonka, V. (1994). Presence of antibodies to seven human papillomavirus type 16-derived peptides in cervical cancer patients and healthy controls. J Infect Dis 170, 1424-1431.
11. Han, R., Cladel, N. M., Reed, C. A., Peng, X., Budgeon, L. R., Pickel, M. & Christensen, N. D. (2000a). DNA vaccination prevents and/or delays carcinoma development of papillomavirus-induced skin papillomas on rabbits. J Virol 74, 9712-9716.
12. Han, R., Reed, C. A., Cladel, N. M. & Christensen, N. D. (2000b). Immunization of rabbits with cottontail rabbit papillomavirus E1 and E2 genes: protective immunity induced by gene gun-mediated intracutaneous delivery but not by intramuscular injection. Vaccine 18, 2937-2944.
13. Heino, P., Dillner, J. & Schwartz, S. (1995). Human papillomavirus type-16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. Virology 214, 349-359.
14. Herod, J. J. O., Shafi, M. I., Rollason, T. P., Jordan, J. A. & Luesley, D. M. (1996). Vulvar intraepithelial neoplasia: long term follow up of treated and untreated women. Br J Obstet Gynaecol 103, 446-452.
15. Hildesheim, A., Han, C. L., Brinton, L. A., Kurman, R. J. & Schiller, J. T. (1997). Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: results from a seroepidemiological case-control study. Obstet Gynecol 90, 748-754.
16. Ho, G. Y., Bierman, R., Beardsley, L., Chang, C. J. & Burk, R. D. (1998). Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338, 423-428.
17. Kimbauer, R., Taub, J., Greenstone, H., Roden, R., Durst, M., Gissmann, L., Lowy, D. R. & Schiller, J. T. (1993). Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 67, 6929-6936.
18. Klencke, B., Matijevic, M., Urban, R. G. & 10 other authors (2002). Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a phase I study of ZYC101. Clin Cancer Res 8, 1028-1037.
19. Lehtinen, M., Leminen, A., Kuoppala, T., Tiikkainen, M., Lehtinen, T., Lehtovirta, P., Punnonen, R., Vesterinen, E. & Paavonen, J. (1992). Pre- and post-treatment serum antibody responses to HPV-16 E2 and HSV 2 ICP8 proteins in women with cervical carcinoma. J Med Virol 37, 180-186.
20. Lenner, P., Dillner, J., Wiklund, F., Hallmans, G. & Stendahl, U. (1995). Serum antibody responses against human papillomavirus in relation to tumor characteristics, response to treatment, and survival in carcinoma of the uterine cervix. Cancer Immunol Immunother 40, 201-205.
21. Lenz, P., Day, P. M., Pang, Y. Y., Frye, S. A., Jensen, P. N., Lowy, D. R. & Schiller, J. T. (2001). Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 166, 5346-5355.
22. Muderspach, L., Wilczynski, S., Roman, L. & 7 other authors (2000). A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV-16 positive. Clin Cancer Res 6, 3406-3416.
23. Peitsaro, P., Johansson, B. & Syrjanen, S. (2002). Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 40, 886-891.
24. Rocha-Zavaleta, L., Jordan, D., Pepper, S. & 7 other authors (1997). Differences in serological IgA responses to recombinant baculovirus-derived human papillomavirus E2 protein in the natural history of cervical neoplasia. Brit J Cancer 75, 1144-1150.
25. Rozendaal, L., Walboomers, J. M. M. & Van der Linden, J. C. (1996). High risk human papillomavirus in cytomorphological normal smears has a high predictive value for development of severe dysplasia. Int J Cancer 68, 766-769.
26. Rudolf, M. P., Fausch, S. C., Da Silva, D. M. & Kest, W. M. (2001). Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol 166, 5917-5924.
27. Sallusto, F., Lenig, D., Forster, R., Lipp, M. & Lanzavecchia, A. (1999). Two subsets of memory T lymphocytes with distinct homing potentials and effector functions [see comments]. Nature 401, 708-712.
28. Santin, A. D., Bellone, S., Gokden, M., Cannon, M. J. & Parham, G. P. (2002). Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 346, 1752-1753.
29. Schiller, J. T. & Hildesheim, A. (2000). Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report. J Clin Virol 19, 67-74.
30. Sehr, P., Zumbach, K. & Pawlita, M. (2001). A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: validation for HPV serology. J Immunol Methods 253, 153-162.
31. Sehr, P., Muller, M., Hopfl, R., Widschwendter, A. & Pawlita, M. (2002). HPV- antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods 106, 61-70.
32. Shah, K. V., Viscidi, R. P., Alberg, A. J., Heizisouer, K. J. & Comstock, G. W. (1997). Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomark Prev 6, 233-237.
33. Soler, C., Allibert, P., Chardonnet Y., Cros, P., Mandrand, B. & Thivolet, J. (1991). Detection of human papillomavirus types 6, 11, 16 and 18 in mucosal and cutaneous lesions by the multiplex polymerase chain reaction. J Virol Methods 35, 143-157.
34. +-T-cell responses to human papillomavirus type 1 antigens expressed at various stages of the virus life cycle by using an enzyme-linked immunospot assay of gamma interferon release. J Virol 76, 6027-6036.
35. Stevenson, M., Hudson, L. C., Burns, J. E., Stewart, R. L., Wells, M. & Maitland, N. J. (2000). Inverse relationship between the expression of the human papillomavirus type 16 transcription factor E2 and virus DNA copy number during the progression of cervical intraepithelial neoplasia. J Gen Virol 81, 1825-1832.
36. Sun, Y., Hildesheim, A., Brinton, L. A., Nasca, P. C., Trimble, C. L., Kurman, R. J., Viscidi, R. P. & Shah, K. V. (1996). Human papillomavirus-specific serologic response in vulvar neoplasia. Gynecol Oncol 63, 200-203.
37. Tindle, R. W. (2002). Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer 2, 59-65.
38. Tonon, S. A., Picconi, M. A., Bos, P. D., Zinovich, J. B., Galuppo, J., Alonio, L. V. & Teyssie, A. R. (2001). Physical status of the E2 human papillomavirus 16 viral gene in cervical preneoplastic and neoplastic lesions. J Clin Virol 21, 129-134.
39. van Beurden, M., ten Kate, F. J., Smits, H. L., Berkhout, R. J., de Craen, A. J., van der Vange, N., Lammes, F. B. & ter Schegget, J. (1995). Multifocal vulvar intraepithelial neoplasia grade III and multicentric lower genital tract neoplasia is associated with transcriptionally active human papillomavirus. Cancer 75, 2879-2884.
40. van der Burg, S. H., Ressing, M. E., Kwappenberg, K. M. C. & 11 other authors (2001). Natural T-helper immunity against human papillomavirus type 16 (HPV-16) E7-derived peptide epitopes in patients with HPV-16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. Int J Cancer 91, 612-618.
41. Wang, Z., Christensen, N., Schiller, J. T. & Dillner, J. (1997). A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol 78, 2209-2215.
42. Webster, K., Parish, J., Pandya, M., Stern, P. L., Clarke, A. R. & Gaston, K. (2000). The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J Biol Chem 275, 87-94.
43. Wikstrom, A., Vandoornum, G. J. J., Quint, W. G. V., Schiller, J. T. & Dillner, J. (1995). Identification of human papillomavirus sero-conversions. J Gen Virol 76, 529-539.
44. + T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types. J Virol 76, 7418-7429.
45. Zhou, J., Sun, X. Y., Davies, H., Crawford, L., Park, D. & Frazer, I. H. (1992). Definition of linear antigenic regions of the HPV-16 L1 capsid protein using synthetic virion-like particles. Virology 189, 592-599.